Tempo Therapeutics Announces First Patient Dosed in Clinical Trial of TT101 For Tissue Repair in Skin Cancer Surgery13 Sep at 4:41 pm
Tempo Therapeutics Secures Series A Financing to Advance Cutting-Edge Tissue Scaffold Products into Clinical Trials19 Mar at 1:45 pm
